|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 USD | +3.90% |
|
+5.45% | -36.61% |
Poseida Therapeutics, Inc. approved a leadership transition appointing Kristin Yarema, Ph.D., as President of the Company. Dr. Yarema currently serves as President, Cell Therapy of the Company. The Board also appointed Mark Gergen, the Company?s current President and Chief Executive Officer, as Executive Chairman of the Board.
The leadership transition is anticipated to be effective as of January 1, 2024.
| 1st Jan change | Capi. | |
|---|---|---|
| -36.61% | 206M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
POSEIDA THERAPEUTICS, INC. 
